IRWD Ironwood Pharmaceuticals Inc

Price (delayed)

$11.86

Market cap

$1.82B

P/E Ratio

3.64

Dividend/share

N/A

EPS

$3.26

Enterprise value

$1.77B

Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the ...

Highlights
IRWD's P/E is 7% below its last 4 quarters average of 3.9
Ironwood Pharmaceuticals's gross profit has increased by 6% YoY and by 2.1% QoQ
The quick ratio has dropped by 79% year-on-year but it has increased by 3.2% since the previous quarter
IRWD's debt is up by 15% year-on-year and by 13% since the previous quarter
The company's equity fell by 15% QoQ

Key stats

What are the main financial stats of IRWD
Market
Shares outstanding
153.84M
Market cap
$1.82B
Enterprise value
$1.77B
Valuations
Price to earnings (P/E)
3.64
Price to book (P/B)
3.65
Price to sales (P/S)
4.43
EV/EBIT
7.29
EV/EBITDA
7.24
EV/Sales
4.18
Earnings
Revenue
$422.44M
EBIT
$242.63M
EBITDA
$244.1M
Free cash flow
$252.05M
Per share
EPS
$3.26
Free cash flow per share
$1.6
Book value per share
$3.25
Revenue per share
$2.68
TBVPS
$6.86
Balance sheet
Total assets
$1.08B
Total liabilities
$565.6M
Debt
$537.66M
Equity
$517.78M
Working capital
$562.7M
Liquidity
Debt to equity
1.04
Current ratio
4.82
Quick ratio
4.85
Net debt/EBITDA
-0.23
Margins
EBITDA margin
57.8%
Gross margin
100%
Net margin
124.8%
Operating margin
57.9%
Efficiency
Return on assets
49.1%
Return on equity
95.2%
Return on invested capital
28.6%
Return on capital employed
25.9%
Return on sales
57.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IRWD stock price

How has the Ironwood Pharmaceuticals stock price performed over time
Intraday
-0.08%
1 week
2.86%
1 month
-1.9%
1 year
-3.58%
YTD
1.72%
QTD
2.86%

Financial performance

How have Ironwood Pharmaceuticals's revenue and profit performed over time
Revenue
$422.44M
Gross profit
$422.44M
Operating income
$244.71M
Net income
$527.32M
Gross margin
100%
Net margin
124.8%
The operating income has increased by 40% YoY and by 5% from the previous quarter
IRWD's operating margin is up by 32% year-on-year and by 3.2% since the previous quarter
Ironwood Pharmaceuticals's gross profit has increased by 6% YoY and by 2.1% QoQ
IRWD's revenue is up by 6% YoY and by 2.1% QoQ

Growth

What is Ironwood Pharmaceuticals's growth rate over time

Valuation

What is Ironwood Pharmaceuticals stock price valuation
P/E
3.64
P/B
3.65
P/S
4.43
EV/EBIT
7.29
EV/EBITDA
7.24
EV/Sales
4.18
IRWD's P/E is 7% below its last 4 quarters average of 3.9
The company's equity fell by 15% QoQ
IRWD's P/S is 19% below its 5-year quarterly average of 5.5 and 10% below its last 4 quarters average of 4.9
IRWD's revenue is up by 6% YoY and by 2.1% QoQ

Efficiency

How efficient is Ironwood Pharmaceuticals business performance
Ironwood Pharmaceuticals's return on assets has surged by 80% YoY but it has decreased by 11% QoQ
Ironwood Pharmaceuticals's return on equity has shrunk by 76% YoY and by 19% QoQ
The return on sales has increased by 30% year-on-year and by 2.5% since the previous quarter
Ironwood Pharmaceuticals's ROIC has decreased by 4% from the previous quarter

Dividends

What is IRWD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRWD.

Financial health

How did Ironwood Pharmaceuticals financials performed over time
The total assets is 92% more than the total liabilities
The total assets has soared by 81% YoY but it has contracted by 3.9% from the previous quarter
Ironwood Pharmaceuticals's current ratio has plunged by 79% YoY but it has increased by 4.6% from the previous quarter
IRWD's debt is 3.8% greater than its equity
The company's debt to equity has shrunk by 75% YoY but it rose by 32% QoQ
IRWD's debt is up by 15% year-on-year and by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.